Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combina... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase Ib, Open-Label, Multicenter Study of EBC-129 Combined With Osimertinib in Patients With A... Read More
U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07838610) titled 'Additional Effects of Thoracic Mobilization Versus Manipulation Along With Standard Physic... Read More
U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07839026) titled 'Greek Connections Study' on Sept. 18. Brief Summary: The purpose of this study is to eval... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Co... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared ... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemother... Read More
U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07838623) titled 'Comparison Between Kaltenborn and Mulligan Mobilization in Forward Head Posture' on Sept. ... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A longitudinal study to investigate innate immune reprogramming following Herpes Zoster vaccinati... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'Phase I/II study of Mezigdomide and Elranatamab for relapsed/refractory multiple myeloma patients... Read More